Gene · 1890
Papers4,467
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 4,467
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 1,3,4-Oxadiazole: An Emerging Scaffold to Inhibit the Thymidine Phosphorylase as an Anticancer Agent. | Curr Med Chem | 2024 | 37438902 | PubTator, text mining | PubMed |
| Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling. | Front Pharmacol | 2023 | 38269272 | PubTator, text mining | PubMed |
| Clinical Phase I Study of TAS102/Irinotecan/Bevacizumab Combination Therapy in Japanese Patients With Unresectable Metastatic Colorectal Cancer (mCRC). | Cureus | 2023 | 38222210 | PubTator, text mining | PubMed |
| An Efficient Synthesis of 1-(1,3-Dioxoisoindolin-2-yl)-3-aryl Urea Analogs as Anticancer and Antioxidant Agents: An Insight into Experimental and In Silico Studies. | Molecules | 2023 | 38202650 | PubTator, text mining | PubMed |
| A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer. | J Clin Med | 2023 | 38202064 | PubTator, text mining | PubMed |
| Deciphering Urogenital Cancers through Proteomic Biomarkers: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 | 38201450 | PubTator, text mining | PubMed |
| Capecitabine for Salvage Treatment of Patients With Heavily Pretreated Human Papillomavirus-Associated Oropharynx Cancer With Distant Metastases. | J Adv Pract Oncol | 2023 | 38196671 | PubTator, text mining | PubMed |
| Camrelizumab and apatinib combined with chemotherapy in perioperative effective therapy for advanced gastric carcinoma with peritoneal metastasis: a case report. | J Gastrointest Oncol | 2023 | 38196525 | PubTator, text mining | PubMed |
| Angiogenesis inhibitors for metastatic colorectal cancer. | Transl Cancer Res | 2023 | 38192992 | PubTator, text mining | PubMed |
| Case report: The use of PRP in the treatment of diabetic foot: case series and a review of the literature. | Front Endocrinol (Lausanne) | 2023 | 38170077 | PubTator, text mining | PubMed |
| The genetic puzzle of a SOD1-patient with ocular ptosis and a motor neuron disease: a case report. | Front Genet | 2023 | 38152653 | PubTator, text mining | PubMed |
| A Rare Case on Capecitabine Induced Acquired Palmoplantar Keratoderma. | Clin Cosmet Investig Dermatol | 2023 | 38152152 | PubTator, text mining | PubMed |
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis. | Cancers (Basel) | 2023 | 38136304 | PubTator, text mining | PubMed |
| Using machine learning model explanations to identify proteins related to severity of meibomian gland dysfunction. | Sci Rep | 2023 | 38135766 | PubTator, text mining | PubMed |
| Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study. | Transl Cancer Res | 2023 | 38130300 | PubTator, text mining | PubMed |
| The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. | Cell Death Dis | 2023 | 38104141 | PubTator, text mining | PubMed |
| Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies reveals potential therapeutic strategies. | Cell Rep Med | 2023 | 38086380 | PubTator, text mining | PubMed |
| Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. | World J Gastrointest Oncol | 2023 | 38077638 | PubTator, text mining | PubMed |
| Red Flags in Primary Mitochondrial Diseases: What Should We Recognize? | Int J Mol Sci | 2023 | 38069070 | PubTator, text mining | PubMed |
| The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects. | Nutrients | 2023 | 38068715 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1890/papers?page=9